Mariner’s Evolent Health EVH Stock Holding History

Mariner’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02M	Buy	371,753 +140,159	+61%	+$537K	﹤0.01%	1491
2026 Q1	$528K	Buy	231,594 +119,486	+107%	+$379K	﹤0.01%	2456
2025 Q4	$448K	Buy	112,108 +43,967	+65%	+$244K	﹤0.01%	2513
2025 Q3	$576K	Sell	68,141 -13,547	-17%	-$131K	﹤0.01%	2316
2025 Q2	$920K	Sell	81,688 -3,702	-4%	-$34K	﹤0.01%	1854
2025 Q1	$809K	Buy	+85,390	New	+$863K	﹤0.01%	1835

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mariner's EVH Position: Q2 2026 in Review

Mariner increased its Evolent Health (EVH) stake by 61% in Q2 2026, buying an estimated $537K and bringing the position to 371,753 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Mariner first reported a position in EVH in Q1 2025 and has held it in 6 quarters since. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Mariner held 371,753 shares of Evolent Health worth $2.02M as of Q2 2026.
Mariner bought 140,159 Evolent Health shares in Q2 2026, an estimated $537K.
Evolent Health made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1491 holding.
Mariner first reported a position in Evolent Health in Q1 2025 and has held it in 6 quarters since.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.